WASHINGTON / RankWire.AI / – A groundbreaking discovery reveals that a scarce inherited genetic mutation can increase an individual’s likelihood of developing lung cancer by approximately 25 times overall, and by about 60 times among those who have never smoked, according to a pivotal study published in the journal Science. The research, carried out by scientists at the Dana-Farber Cancer Institute in collaboration with the 23andMe Research Institute, analyzed anonymized genetic data from over 3.3 million people. The investigators pinpointed the germline variation, designated as EGFR T790M, as one of the most potent inherited risk factors for lung cancer identified so far.
This mutation affects the epidermal growth factor receptor gene, which plays a key role in controlling cell growth and division within lung tissue. While somatic mutations in the EGFR gene, acquired during a person’s life, are known to drive non-small cell lung cancer, the T790M germline variant is inherited from birth and exists in every cell. Data from the National Cancer Institute indicates that this mutation appears in roughly 1 in every 15,850 individuals in the United States. Lead author Dr. Jaclyn LoPiccolo highlighted that carriers of the variant face about a 62-fold increase in lung cancer risk among never-smokers, compared to approximately 11 times in those with a history of smoking.
Genetic mapping traced the EGFR T790M variant mainly to populations in Southern Appalachia, specifically across Tennessee and Alabama. Evolutionary geneticists traced its origins back to British and Irish settlers who migrated to North America during colonial times. The mutation’s prevalence increased after a genetic bottleneck about 200 years ago. Dr. Pasi A. Jänne, senior author of the study, emphasized that although lung cancer screening currently primarily focuses on tobacco exposure, recognizing robust genetic risk factors could lead to targeted screening approaches such as low-dose computed tomography in non-smoker carriers.
Gene Could Elevate Lung Cancer Risk by Nearly 60 Times in Non-Smokers
Supported by the National Institutes of Health, preclinical and clinical studies confirmed that this mutation shows a strong, specific link to lung cancer, with no significant association found with 17 other common cancers analyzed in the dataset. Oncologists pointed out that although tobacco use remains the leading overall cause of lung cancer, the rise of lung cancer cases among non-smokers is becoming a significant global health concern. Major pharmaceutical companies, including AstraZeneca, are actively developing targeted therapies such as Tagrisso, which are tyrosine kinase inhibitors designed to treat EGFR-mutant lung tumors once they progress.
Co-lead researcher Dr. Alexander Gusev remarked that this study illustrates how a single inherited point mutation can have an extraordinarily strong impact on disease susceptibility. Medical professionals suggest that individuals with multiple family members affected by lung cancer, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia should consult genetic counselors. Researchers noted that possessing the mutation does not guarantee lung cancer development, as environmental factors and additional genetic changes play a role in whether malignant transformation occurs over a person’s lifetime.
Multicenter Study Examines Genetic Data from Over Three Million Participants
The research consortium aims to broaden observational efforts through the ongoing INHERIT Study, focusing on additional inherited EGFR variants among diverse racial groups. The longitudinal approach will aim to identify specific environmental factors and secondary genetic alterations that explain why some carriers develop tumors while others remain unaffected.
Findings related to population genetics, risk assessments, and screening strategies are available via peer-reviewed medical repositories and official institutional channels. Researchers will present updated biomarker data at upcoming international oncology meetings to help shape future guidelines for lung cancer screening.